Taiho has a long history of developing new therapeutic options to serve the needs of oncologists and cancer patients. Our development of TAS-102 is an example of our commitment to patients diagnosed with metastatic colorectal cancer whose disease progressed after or who were intolerant to standard therapies.
At the same time, we recognize the importance of collaborating with academia and biotech ventures outside Japan for efficient and effective biopharmaceutical innovation.
Taiho hopes to use the investment in Remiges Fund as the platform for open innovation – an outreach for innovative technologies. Through Remiges’ well-connected US-Japan cross border investment team, Taiho will be tapping into the US/Europe biotech start-up community and catalyze the company’s R&D to deliver innovative cancer treatment to patients.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.
Taiho also aims to offer over-the-counter medicinal products that support people’s efforts to lead fulfilling and rewarding lives.